Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration

Marius Rademaker, Karen Agnew, Megan Andrews, Katherine Armour, Chris Baker, Peter Foley, John Frew, Kurt Gebauer, Monisha Gupta, Debra Kennedy, Gillian Marshman, John Sullivan

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

The Australasian Psoriasis Collaboration has reviewed the evidence for managing moderate to severe psoriasis in those who are pregnant or are breast-feeding, or planning a family. The severity of the psoriasis, associated comorbidities and specific anti-psoriasis treatment, along with other exposures, can have a deleterious effect on pregnancy outcomes. Psoriasis itself increases the risk of preterm and low birthweight babies, along with spontaneous and induced abortions, but no specific birth defects have been otherwise demonstrated. The baseline risk for a live born baby to have a major birth defect is 3%, and significant neuro-developmental problem is 5%. In Australia, pregnant women with psoriasis are more likely to be overweight or obese, depressed, or smoke in their first trimester, and are also less likely to take prenatal vitamins or supplements. Preconception counselling to improve maternal, pregnancy and baby health is therefore strongly encouraged. The topical and systemic therapies commonly used in psoriasis are each discussed separately, with regards to pregnancy exposure, breast-feeding and effects on male fertility and mutagenicity. The systemic therapies included are acitretin, adalimumab, apremilast, certolizumab, ciclosporin, etanercept, infliximab, ixekizumab, methotrexate, NBUVB, prednisone, PUVA, secukinumab and ustekinumab. The topical therapies include dithranol (anthralin), calcipotriol, coal tar, corticosteroids (weak, potent and super-potent), moisturisers, salicylic acid, tacrolimus, and tazarotene. As a general recommendation, effective drugs that have been widely used for years are preferable to newer alternatives with less foetal safety data. It is equally important to evaluate the risks of not treating, as severe untreated disease may negatively impact both mother and the foetus.

Original languageEnglish
Pages (from-to)86-100
Number of pages15
JournalAustralasian Journal of Dermatology
Volume59
Issue number2
DOIs
Publication statusPublished - 1 May 2018

Fingerprint

Family Planning Services
Breast Feeding
Psoriasis
Anthralin
LY2439821
Acitretin
Coal Tar
Pregnancy
Salicylic Acid
Induced Abortion
Tacrolimus
Spontaneous Abortion
First Pregnancy Trimester
Therapeutics
Pregnancy Outcome
Prednisone
Methotrexate
Vitamins
Smoke
Cyclosporine

Cite this

Rademaker, M., Agnew, K., Andrews, M., Armour, K., Baker, C., Foley, P., ... Sullivan, J. (2018). Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australasian Journal of Dermatology, 59(2), 86-100. https://doi.org/10.1111/ajd.12641
Rademaker, Marius ; Agnew, Karen ; Andrews, Megan ; Armour, Katherine ; Baker, Chris ; Foley, Peter ; Frew, John ; Gebauer, Kurt ; Gupta, Monisha ; Kennedy, Debra ; Marshman, Gillian ; Sullivan, John. / Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. In: Australasian Journal of Dermatology. 2018 ; Vol. 59, No. 2. pp. 86-100.
@article{77b572d67ced414783b6e73fa3b8e727,
title = "Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration",
abstract = "The Australasian Psoriasis Collaboration has reviewed the evidence for managing moderate to severe psoriasis in those who are pregnant or are breast-feeding, or planning a family. The severity of the psoriasis, associated comorbidities and specific anti-psoriasis treatment, along with other exposures, can have a deleterious effect on pregnancy outcomes. Psoriasis itself increases the risk of preterm and low birthweight babies, along with spontaneous and induced abortions, but no specific birth defects have been otherwise demonstrated. The baseline risk for a live born baby to have a major birth defect is 3{\%}, and significant neuro-developmental problem is 5{\%}. In Australia, pregnant women with psoriasis are more likely to be overweight or obese, depressed, or smoke in their first trimester, and are also less likely to take prenatal vitamins or supplements. Preconception counselling to improve maternal, pregnancy and baby health is therefore strongly encouraged. The topical and systemic therapies commonly used in psoriasis are each discussed separately, with regards to pregnancy exposure, breast-feeding and effects on male fertility and mutagenicity. The systemic therapies included are acitretin, adalimumab, apremilast, certolizumab, ciclosporin, etanercept, infliximab, ixekizumab, methotrexate, NBUVB, prednisone, PUVA, secukinumab and ustekinumab. The topical therapies include dithranol (anthralin), calcipotriol, coal tar, corticosteroids (weak, potent and super-potent), moisturisers, salicylic acid, tacrolimus, and tazarotene. As a general recommendation, effective drugs that have been widely used for years are preferable to newer alternatives with less foetal safety data. It is equally important to evaluate the risks of not treating, as severe untreated disease may negatively impact both mother and the foetus.",
keywords = "acitretin, biological therapy, ciclosporin, corticosteroid, methotrexate, topical therapy",
author = "Marius Rademaker and Karen Agnew and Megan Andrews and Katherine Armour and Chris Baker and Peter Foley and John Frew and Kurt Gebauer and Monisha Gupta and Debra Kennedy and Gillian Marshman and John Sullivan",
year = "2018",
month = "5",
day = "1",
doi = "10.1111/ajd.12641",
language = "English",
volume = "59",
pages = "86--100",
journal = "Australian Journal of Dermatology",
issn = "0004-8380",
publisher = "John Wiley & Sons",
number = "2",

}

Rademaker, M, Agnew, K, Andrews, M, Armour, K, Baker, C, Foley, P, Frew, J, Gebauer, K, Gupta, M, Kennedy, D, Marshman, G & Sullivan, J 2018, 'Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration' Australasian Journal of Dermatology, vol. 59, no. 2, pp. 86-100. https://doi.org/10.1111/ajd.12641

Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. / Rademaker, Marius; Agnew, Karen; Andrews, Megan; Armour, Katherine; Baker, Chris; Foley, Peter; Frew, John; Gebauer, Kurt; Gupta, Monisha; Kennedy, Debra; Marshman, Gillian; Sullivan, John.

In: Australasian Journal of Dermatology, Vol. 59, No. 2, 01.05.2018, p. 86-100.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration

AU - Rademaker, Marius

AU - Agnew, Karen

AU - Andrews, Megan

AU - Armour, Katherine

AU - Baker, Chris

AU - Foley, Peter

AU - Frew, John

AU - Gebauer, Kurt

AU - Gupta, Monisha

AU - Kennedy, Debra

AU - Marshman, Gillian

AU - Sullivan, John

PY - 2018/5/1

Y1 - 2018/5/1

N2 - The Australasian Psoriasis Collaboration has reviewed the evidence for managing moderate to severe psoriasis in those who are pregnant or are breast-feeding, or planning a family. The severity of the psoriasis, associated comorbidities and specific anti-psoriasis treatment, along with other exposures, can have a deleterious effect on pregnancy outcomes. Psoriasis itself increases the risk of preterm and low birthweight babies, along with spontaneous and induced abortions, but no specific birth defects have been otherwise demonstrated. The baseline risk for a live born baby to have a major birth defect is 3%, and significant neuro-developmental problem is 5%. In Australia, pregnant women with psoriasis are more likely to be overweight or obese, depressed, or smoke in their first trimester, and are also less likely to take prenatal vitamins or supplements. Preconception counselling to improve maternal, pregnancy and baby health is therefore strongly encouraged. The topical and systemic therapies commonly used in psoriasis are each discussed separately, with regards to pregnancy exposure, breast-feeding and effects on male fertility and mutagenicity. The systemic therapies included are acitretin, adalimumab, apremilast, certolizumab, ciclosporin, etanercept, infliximab, ixekizumab, methotrexate, NBUVB, prednisone, PUVA, secukinumab and ustekinumab. The topical therapies include dithranol (anthralin), calcipotriol, coal tar, corticosteroids (weak, potent and super-potent), moisturisers, salicylic acid, tacrolimus, and tazarotene. As a general recommendation, effective drugs that have been widely used for years are preferable to newer alternatives with less foetal safety data. It is equally important to evaluate the risks of not treating, as severe untreated disease may negatively impact both mother and the foetus.

AB - The Australasian Psoriasis Collaboration has reviewed the evidence for managing moderate to severe psoriasis in those who are pregnant or are breast-feeding, or planning a family. The severity of the psoriasis, associated comorbidities and specific anti-psoriasis treatment, along with other exposures, can have a deleterious effect on pregnancy outcomes. Psoriasis itself increases the risk of preterm and low birthweight babies, along with spontaneous and induced abortions, but no specific birth defects have been otherwise demonstrated. The baseline risk for a live born baby to have a major birth defect is 3%, and significant neuro-developmental problem is 5%. In Australia, pregnant women with psoriasis are more likely to be overweight or obese, depressed, or smoke in their first trimester, and are also less likely to take prenatal vitamins or supplements. Preconception counselling to improve maternal, pregnancy and baby health is therefore strongly encouraged. The topical and systemic therapies commonly used in psoriasis are each discussed separately, with regards to pregnancy exposure, breast-feeding and effects on male fertility and mutagenicity. The systemic therapies included are acitretin, adalimumab, apremilast, certolizumab, ciclosporin, etanercept, infliximab, ixekizumab, methotrexate, NBUVB, prednisone, PUVA, secukinumab and ustekinumab. The topical therapies include dithranol (anthralin), calcipotriol, coal tar, corticosteroids (weak, potent and super-potent), moisturisers, salicylic acid, tacrolimus, and tazarotene. As a general recommendation, effective drugs that have been widely used for years are preferable to newer alternatives with less foetal safety data. It is equally important to evaluate the risks of not treating, as severe untreated disease may negatively impact both mother and the foetus.

KW - acitretin

KW - biological therapy

KW - ciclosporin

KW - corticosteroid

KW - methotrexate

KW - topical therapy

UR - http://www.scopus.com/inward/record.url?scp=85045665623&partnerID=8YFLogxK

U2 - 10.1111/ajd.12641

DO - 10.1111/ajd.12641

M3 - Review article

VL - 59

SP - 86

EP - 100

JO - Australian Journal of Dermatology

JF - Australian Journal of Dermatology

SN - 0004-8380

IS - 2

ER -